Showing results (211-220 of 349) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|August 24, 2010
Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphismSzu-Chin Li, Yi-Chun Chen, Andrew M Evens, et al.
Oncotarget|June 2, 2018
Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panelJ Tyson McDonald, Athena Kritharis, Afshin Beheshti, et al.
Journal of Substance Abuse Treatment|May 22, 2007
Individual and system influences on waiting time for substance abuse treatmentCarey J A Carr, Jiangmin Xu, Cristina Redko, et al.
European Journal of Immunology|March 8, 2011
FOXP3+ CD4+ Tregs lose suppressive potential but remain anergic during transient inflammation in humanAlvin W L Schadenberg, Sebastiaan J Vastert, Fabiola C M Evens, et al.
Oncotarget|October 4, 2018
Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panelJ Tyson McDonald, Athena Kritharis, Afshin Beheshti, et al.
Annales De Dermatologie Et De Venereologie|February 22, 2011
[Measles in adults: an emerging disease not sparing medical staff]G Monsel, C Rapp, T-A Duong, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 2, 2023
The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional surveyDarcy R Flora, Andrew M Evens, Nicholas Liu, et al.
British Journal of Haematology|February 7, 2024
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional surveyDarcy R Flora, Susan K Parsons, Nicholas Liu, et al.
JCO Oncology Practice|March 22, 2023
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT StudySusan K Parsons, Kristina S Yu, Nicholas Liu, et al.
Leukemia & Lymphoma|August 22, 2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidationRupali Roy, Andrew M Evens, David Patton, et al.
Pageof 35